1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 5
FEATURED COMPANIES
- Bausch Health Companies
- Mylan
- Recordati
- TSUMURA
- MORE
The increase in strategic alliances to help market grow. Pharmaceutical companies are engaging in strategic alliances for the development of medications for the treatment of Wilson’s disease. These alliances enhance the R&D activities for new drugs for the treatment of Wilson’s disease. The analysts have predicted that the Wilson’s disease drugs market will register a CAGR of almost 6% by 2023.
Market Overview
Increasing introduction of patient assistance programs
Patient assistance programs have been introduced to help patients who lack health insurance or prescription drug coverage to obtain the medications they need.
High cost of treatment
Despite the benefits of chelators, the price of these medicines poses a challenge to the market growth. The high cost of chelators will result in low patient adherence to chelator therapy. This, in turn, will hinder the growth of the global Wilson’s disease drugs market.
For the detailed list of factors that will drive and challenge the growth of the Wilson’s disease drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Bausch Health Companies and Mylan the competitive environment is quite intense. Factors such as the rising increase in strategic alliances and increasing introduction of patient assistance programs, will provide considerable growth opportunities to Wilson’s disease drugs manufactures. Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. The strategic alliances enhance the R&D activities for new drugs for the treatment of Wilson’s disease. Such alliances help companies develop new drugs for the treatment of Wilson’s disease. It also helps in the faster development of therapeutic products.’
Market Overview
Increasing introduction of patient assistance programs
Patient assistance programs have been introduced to help patients who lack health insurance or prescription drug coverage to obtain the medications they need.
High cost of treatment
Despite the benefits of chelators, the price of these medicines poses a challenge to the market growth. The high cost of chelators will result in low patient adherence to chelator therapy. This, in turn, will hinder the growth of the global Wilson’s disease drugs market.
For the detailed list of factors that will drive and challenge the growth of the Wilson’s disease drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Bausch Health Companies and Mylan the competitive environment is quite intense. Factors such as the rising increase in strategic alliances and increasing introduction of patient assistance programs, will provide considerable growth opportunities to Wilson’s disease drugs manufactures. Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. The strategic alliances enhance the R&D activities for new drugs for the treatment of Wilson’s disease. Such alliances help companies develop new drugs for the treatment of Wilson’s disease. It also helps in the faster development of therapeutic products.’
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Bausch Health Companies
- Mylan
- Recordati
- TSUMURA
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global rare disease drugs market
Exhibit 02: Segments of global rare disease drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Inheritance of Wilson’s disease
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Chelators: Mechanism of action
Exhibit 21: Chelators - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Chelators - Year-over-year growth 2019-2023 (%)
Exhibit 23: Minerals - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Minerals - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: Country_Legend_2
Exhibit 36: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Country_Legend_3
Exhibit 40: Key leading countries
Exhibit 41: Country_Legend_16
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor_analysis
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Bausch Health Companies - Vendor overview
Exhibit 53: Bausch Health Companies - Business segments
Exhibit 54: Bausch Health Companies - Organizational developments
Exhibit 55: Bausch Health Companies - Geographic focus
Exhibit 56: Bausch Health Companies - Segment focus
Exhibit 57: Bausch Health Companies - Key offerings
Exhibit 58: Bausch Health Companies - Key customers
Exhibit 59: Mylan - Vendor overview
Exhibit 60: Mylan - Business segments
Exhibit 61: Mylan - Organizational developments
Exhibit 62: Mylan - Geographic focus
Exhibit 63: Mylan - Key offerings
Exhibit 64: Mylan - Key customers
Exhibit 65: Recordati - Vendor overview
Exhibit 66: Recordati - Business segments
Exhibit 67: Recordati - Organizational developments
Exhibit 68: Recordati - Geographic focus
Exhibit 69: Recordati - Segment focus
Exhibit 70: Recordati - Key offerings
Exhibit 71: Recordati - Key customers
Exhibit 72: Teva Pharmaceutical Industries - Vendor overview
Exhibit 73: Teva Pharmaceutical Industries - Business segments
Exhibit 74: Teva Pharmaceutical Industries - Organizational developments
Exhibit 75: Teva Pharmaceutical Industries - Geographic focus
Exhibit 76: Teva Pharmaceutical Industries - Segment focus
Exhibit 77: Teva Pharmaceutical Industries - Key offerings
Exhibit 78: Teva Pharmaceutical Industries - Key customers
Exhibit 79: TSUMURA - Vendor overview
Exhibit 80: TSUMURA - Business segments
Exhibit 81: TSUMURA - Organizational developments
Exhibit 82: TSUMURA - Key offerings
Exhibit 83: TSUMURA - Key customers
Exhibit 84: Research framework
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: Information sources
Exhibit 87: List of abbreviations
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Chelators - Market size and forecast 2018-2023
- Minerals - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bausch Health Companies
- Mylan
- Recordati
- Teva Pharmaceutical Industries
- TSUMURA
- Research methodology
- List of abbreviations
Exhibit 01: Global rare disease drugs market
Exhibit 02: Segments of global rare disease drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Inheritance of Wilson’s disease
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Chelators: Mechanism of action
Exhibit 21: Chelators - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Chelators - Year-over-year growth 2019-2023 (%)
Exhibit 23: Minerals - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Minerals - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: Country_Legend_2
Exhibit 36: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Country_Legend_3
Exhibit 40: Key leading countries
Exhibit 41: Country_Legend_16
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor_analysis
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Bausch Health Companies - Vendor overview
Exhibit 53: Bausch Health Companies - Business segments
Exhibit 54: Bausch Health Companies - Organizational developments
Exhibit 55: Bausch Health Companies - Geographic focus
Exhibit 56: Bausch Health Companies - Segment focus
Exhibit 57: Bausch Health Companies - Key offerings
Exhibit 58: Bausch Health Companies - Key customers
Exhibit 59: Mylan - Vendor overview
Exhibit 60: Mylan - Business segments
Exhibit 61: Mylan - Organizational developments
Exhibit 62: Mylan - Geographic focus
Exhibit 63: Mylan - Key offerings
Exhibit 64: Mylan - Key customers
Exhibit 65: Recordati - Vendor overview
Exhibit 66: Recordati - Business segments
Exhibit 67: Recordati - Organizational developments
Exhibit 68: Recordati - Geographic focus
Exhibit 69: Recordati - Segment focus
Exhibit 70: Recordati - Key offerings
Exhibit 71: Recordati - Key customers
Exhibit 72: Teva Pharmaceutical Industries - Vendor overview
Exhibit 73: Teva Pharmaceutical Industries - Business segments
Exhibit 74: Teva Pharmaceutical Industries - Organizational developments
Exhibit 75: Teva Pharmaceutical Industries - Geographic focus
Exhibit 76: Teva Pharmaceutical Industries - Segment focus
Exhibit 77: Teva Pharmaceutical Industries - Key offerings
Exhibit 78: Teva Pharmaceutical Industries - Key customers
Exhibit 79: TSUMURA - Vendor overview
Exhibit 80: TSUMURA - Business segments
Exhibit 81: TSUMURA - Organizational developments
Exhibit 82: TSUMURA - Key offerings
Exhibit 83: TSUMURA - Key customers
Exhibit 84: Research framework
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: Information sources
Exhibit 87: List of abbreviations
Note: Product cover images may vary from those shown
3 of 5
FEATURED COMPANIES
- Bausch Health Companies
- Mylan
- Recordati
- TSUMURA
- MORE
Global Wilson’s Disease Drugs Market 2019-2023
The author of the report recognizes the following companies as the key players in the global Wilson’s disease drugs market: Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in strategic alliances.”
According to the report, one of the major drivers for this market is the Increasing introduction of patient assistance programs.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global Wilson’s disease drugs market: Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in strategic alliances.”
According to the report, one of the major drivers for this market is the Increasing introduction of patient assistance programs.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
- Bausch Health Companies
- Mylan
- Recordati
- Teva Pharmaceutical Industries
- TSUMURA
Note: Product cover images may vary from those shown
5 of 5
LOADING...
